MAPT and Alzheimer disease: With the continuous research and development on AD biomarker and its application in diagnostic setting, Jack and colleagues [7] proposed the “ATN” framework, which classified biomarkers into A (amyloid), T (phosphorylated tau) and N (neurodegeneration and neuronal injury) in 2018.